文献速递类风湿关节炎其他结缔组织病

类风湿关节炎及其表型亚组与重症COVID-19结局风险的相关性:一项回顾性、比较性、多中心队列研究

Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study.
PubMed 文献 · Lancet Rheumatol · 2022-09-13

这项在美国两个大型医疗系统开展的回顾性、比较性、多中心队列研究,将582例类风湿关节炎患者与2875例匹配对照比较,发现类风湿关节炎患者重症COVID-19风险升高(HR 1.75),其中合并间质性肺病者风险最高(HR 2.50)。

要点

  • 类风湿关节炎患者重症COVID-19风险高于对照(HR 1.75,95%CI 1.45-2.10)。
  • 合并间质性肺病者风险最高(HR 2.50,95%CI 1.66-3.77)。
  • 血清阳性或骨侵蚀者风险亦升高(HR 1.97、1.93)。

核心结论

  • 类风湿关节炎患者在各表型亚组中重症COVID-19风险均升高,合并间质性肺病者尤为明显。
  • 作者认为,类风湿关节炎合并间质性肺病或其治疗可能是重症COVID-19结局的重要促成因素。

研究设计与样本

  • 回顾性、比较性、多中心队列研究,在美国Mayo Clinic(19家医院及附属门诊中心)和Mass General Brigham(14家医院及附属门诊中心)两个大型医疗系统开展。
  • 纳入符合2010年美国风湿病学会/欧洲抗风湿病联盟分类标准、且2020年3月1日至2021年6月6日期间患COVID-19的连续类风湿关节炎患者582例,按年龄、性别和日历日期1:5匹配无类风湿关节炎对照2875例。
  • 数据来自Mayo Clinic和Mass General Brigham的电子健康记录。
  • 按表型特征分析亚组:类风湿关节炎相关间质性肺病、血清阳性(抗环瓜氨酸肽抗体、类风湿因子或两者兼有)、骨侵蚀。
  • 采用Cox回归估计类风湿关节炎及其亚组相比对照组的重症COVID-19风险比(HR)。

主要发现

  • 类风湿关节炎患者582例中,平均年龄62岁(SD 14),女性421例(72%)、男性161例(28%),白人457例(79%)、西班牙裔或拉丁裔65例(11%)、黑人41例(7%)。
  • 类风湿关节炎患者中,间质性肺病50例(9%/582),血清阳性388例(68%/568),骨侵蚀159例(27%/582)。
  • 重症COVID-19在类风湿关节炎患者中发生126例(22%/582),在对照组中发生363例(13%/2875)。
  • 类风湿关节炎患者相比对照组重症COVID-19的HR为1.75(95%CI 1.45-2.10)。
  • 类风湿关节炎相关间质性肺病患者相比对照组HR为2.50(95%CI 1.66-3.77);血清阳性者HR为1.97(95%CI 1.58-2.46);骨侵蚀者HR为1.93(95%CI 1.41-2.63)。

关键数值与推荐

  • 类风湿关节炎诊断采用2010年美国风湿病学会/欧洲抗风湿病联盟分类标准。
  • 重症COVID-19定义为住院或死亡的复合结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis has been associated with severe COVID-19, but few studies have investigated how phenotypes of rheumatoid arthritis affect these associations. We aimed to investigate the associations between rheumatoid arthritis and phenotypes of interstitial lung disease, serostatus, and bone erosions with COVID-19 severity. METHODS: We did a retrospective, comparative, multicentre cohort study at two large health-care systems (Mayo Clinic [19 hospitals and affiliated outpatient centres] and Mass General Brigham [14 hospitals and affiliated outpatient centres]) in the USA. Consecutive patients with rheumatoid arthritis meeting the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria and who had COVID-19 between March 1, 2020, and June 6, 2021, were matched 1:5 on age, sex, and calendar date with patients without rheumatoid arthritis (comparators). Data were received from electronic health records from Mayo Clinic and Mass General Brigham. We examined subgroups of patients with rheumatoid arthritis by phenotypic features: rheumatoid arthritis-associated interstitial lung disease, seropositivity (for anti-cyclic citrullinated peptide, rheumatoid factor, or both), and bone erosions. Severe COVID-19 was a composite of hospitalisation or death. We used Cox regression to estimate hazard ratios (HR) for severe COVID-19, comparing rheumatoid arthritis and subgroups to the comparator group. FINDINGS: We identified 582 patients with rheumatoid arthritis and 2875 matched comparators, all of whom had COVID-19 within the study dates. The mean age of those with rheumatoid arthritis was 62 [SD 14] years, 421 (72%) of 582 were women and 161 (28%) were men, 457 (79%) were White, 65 (11%) were Hispanic or Latino, and 41 (7%) were Black. Among patients with rheumatoid arthritis, 50 (9%) of 582 had interstitial lung disease, 388 (68%) of 568 were seropositive, and 159 (27%) of 582 had bone erosions. Severe COVID-19 occurred in 126 (22%) of 582 patients with rheumatoid arthritis versus 363 (13%) 2875 in the comparator group. Patients with rheumatoid arthritis had an HR of 1·75 (95% CI 1·45-2·10) for severe COVID-19 versus the comparator group. Patients with rheumatoid arthritis-associated interstitial lung disease had an HR of 2·50 (1·66-3·77) versus the comparator group for severe COVID-19. The risk for severe COVID-19 was also higher in patients with rheumatoid arthritis who were seropositive (HR 1·97 [95% CI 1·58-2·46]) or had erosive disease (1·93 [1·41-2·63]) than for those in the comparator group. INTERPRETATION: Patients with rheumatoid arthritis have an increased risk of severe COVID-19 across phenotypic subgroups, especially among patients with interstitial lung disease. These findings suggest that rheumatoid arthritis with interstitial lung disease, or its treatment, might be a substantial contributor to severe COVID-19 outcomes for patients with rheumatoid arthritis. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO, et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022. PMID: 36118532. doi:10.1016/S2665-9913(22)00227-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。